This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
66
Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
Novo Nordisk Investigational Site
Neuss, Germany
Area under the glucose infusion rate curve during one dosing interval of Insulin Degludec at steady state
Time frame: 0-24 hours after dosing on day 8
Area under the glucose infusion rate curve during one dosing interval of insulin glargine at steady state
Time frame: 0-24 hours after dosing on day 8
Area under the concentration-time curve during one dosing interval at steady state for Insulin Degludec
Time frame: 0-24 hours after dosing on day 8
Area under the concentration-time curve during one dosing interval at steady state for insulin glargine
Time frame: 0-24 hours after dosing on day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.